E-viri
Recenzirano
Odprti dostop
-
Cloyd, Jordan M.; Katz, Matthew H. G.; Prakash, Laura; Varadhachary, Gauri R.; Wolff, Robert A.; Shroff, Rachna T.; Javle, Milind; Fogelman, David; Overman, Michael; Crane, Christopher H.; Koay, Eugene J.; Das, Prajnan; Krishnan, Sunil; Minsky, Bruce D.; Lee, Jeffrey H.; Bhutani, Manoop S.; Weston, Brian; Ross, William; Bhosale, Priya; Tamm, Eric P.; Wang, Huamin; Maitra, Anirban; Kim, Michael P.; Aloia, Thomas A.; Vauthey, Jean-Nicholas; Fleming, Jason B.; Abbruzzese, James L.; Pisters, Peter W. T.; Evans, Douglas B.; Lee, Jeffrey E.
Journal of gastrointestinal surgery, 2017/1, Letnik: 21, Številka: 1Journal Article
Background The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patients with pancreatic ductal adenocarcinoma (PDAC) prior to pancreatoduodenectomy (PD). Methods Consecutive patients (622) with PDAC who underwent PD following chemotherapy and/or chemoradiation between 1990 and 2014 were retrospectively reviewed. Preoperative treatment regimens, clinicopathologic characteristics, operative details, and long-term outcomes in four successive time periods (1990–1999, 2000–2004, 2005–2009, 2010–2014) were evaluated and compared. Results The average number of patients per year who underwent PD following preoperative therapy as well as the proportion of operations performed for borderline resectable and locally advanced (BR/LA) tumors increased over time. The use of induction systemic chemotherapy, as well as postoperative adjuvant chemotherapy, also increased over time. Throughout the study period, the mean EBL decreased while R0 margin rates and vascular resection rates increased overall. Despite the increase in BR/LA resections, locoregional recurrence (LR) rates remained similar over time, and overall survival (OS) improved significantly (median 24.1, 28.1, 37.3, 43.4 months, respectively, p < 0.0001). Conclusions Despite increases in case complexity, relatively low rates of LR have been maintained while significant improvements in OS have been observed. Further improvements in patient outcomes will likely require disruptive advances in systemic therapy.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.